1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Alfresa Holdings Corporation

Alfresa Holdings Corporation

ALFRY
Alfresa Holdings CorporationUS flagOther OTC
13.55
USD
- -
- -
2.46BMarket Cap
Alfresa Holdings Corporation
ALFRY
(Other OTC)

Recent

price

13.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
10,746.34
11,392.31
11,204.2
11,315.3
10,824.31
11,711.63
11,777.42
12,012.93
12,398.25
12,748.7
12,332.8
12,338.56
13,322.54
14,905.63
15,950.69
17,075.1
7,655.29
Revenue per Share
32.42
32.24
97.48
115.5
102.48
158.99
142.57
164.25
195.91
190.26
115.75
153.57
127.42
154.13
147.54
229.64
94.75
Basic EPS, GAAP
199.03
26.58
354.54
-218.69
89.08
107.25
95.69
162.49
155.94
62.61
-186.15
93.33
-61.17
370.49
-78.05
55.23
- -
Free Cash Flow per Basic Share
21.81
22.5
21.87
24
27.35
32.25
34
38
44.2
49
51
54.54
55.04
63.85
67.6
66.15
- -
Dividend per Share
696.12
694.56
742.91
806.02
874.11
1,019.34
1,142.56
1,271.34
1,439.64
1,588.33
1,653.08
1,767.86
1,902.98
2,101.24
2,252.26
2,455.72
2,194.73
Book Value per Share
1,128.6
1,158.87
1,281.2
1,337.52
1,535.59
1,608.2
1,752.58
1,955.88
1,983.1
2,160.29
2,232.32
2,161.81
2,324.83
2,415.8
2,536.02
2,721.69
2,541.65
Tangible Book Value per Share
203
205
213
221
224
220
217
217
213
212
212
210
202
192
186
182
187
Basic Weighted Avg Shares
2,183,356
2,333,465
2,387,435
2,504,574
2,421,105
2,576,360
2,551,919
2,602,925
2,640,529
2,698,555
2,610,521
2,585,643
2,696,069
2,858,500
2,961,051
3,104,064
1,430,644
Sales/Revenue/Turnover
0.43
0.4
0.99
1.4
1.21
1.76
1.3
1.6
1.7
1.77
1.07
1.13
1.12
1.35
1.29
1.17
1.57
Operating Margin (%)
9,340
9,308
10,819
10,011
9,374
10,850
11,017
10,564
10,756
11,777
11,868
12,824
13,302
13,514
14,923
15,048
- -
Depreciation Expense
6,587
6,604
20,771
25,566
22,922
34,975
30,893
35,589
41,724
40,273
24,501
32,182
25,786
29,558
27,389
41,746
17,708
Net Income, GAAP
51.32
56.82
39.06
40.84
38.42
34.6
30.44
30.75
31.8
31.93
32.95
33.16
33.17
32.47
30.29
32.54
33.11
Effective Tax Rate (%)
0.3
0.28
0.87
1.02
0.95
1.36
1.21
1.37
1.58
1.49
0.94
1.24
0.96
1.03
0.92
1.34
1.24
Profit Margin (%)
89,293
91,982
115,917
123,155
132,369
129,623
148,296
166,313
176,873
197,433
208,551
213,658
208,795
214,244
199,535
220,840
211,459
Working Capital
7,235
6,227
5,656
4,338
4,301
4,656
4,530
4,384
4,444
4,873
4,230
3,244
2,461
33,372
33,962
33,933
30,000
LT Debt
236,768
244,014
283,954
305,435
354,120
368,728
393,547
435,932
442,080
474,897
489,957
471,832
488,334
479,858
482,246
507,900
491,309
Total Equity
1.82
1.59
5.06
6.6
5.26
7.82
5.83
6.74
6.68
6.8
3.77
3.94
4.09
5.09
5.07
4.51
2.95
Return on Invested Capital (%)
4.18
4.05
12.77
14.52
11.81
15.86
12.59
13.2
13.97
12.23
7.01
8.8
6.75
7.16
6.17
8.95
4.22
Return on Capital (%)
4.7
4.66
13.82
15.19
12.26
16.66
13.1
13.61
14.34
12.53
7.14
8.93
6.83
7.5
6.67
9.66
4.42
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,565
- -
- -
LT Borrowings
30,000
- -
30,000
LT Finance Leases
3,372
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
187
- -
187
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
1,121,233
- -
1,125,071
Cash, Cash Equivalents & STI
213,756
- -
206,863
Accounts Receivable, Net
646,113
- -
652,172
Inventories
156,377
- -
164,966
Total Current Liabilities
906,989
- -
913,612
Payables & Accruals
- -
- -
- -
ST Debt
1,565
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.34%
0.78%
5.32%
Free Cash Flow
-168.2%
-255.32%
-169.3%
Net Income, GAAP
4.93%
14.24%
52.42%
Sales/Revenue/Turnover
1.92%
3.55%
4.83%
Total Cash Common Dividend
5.58%
2.32%
-4.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
709,056
718,800
751,947
678,697
2,858,500
2025
- -
- -
- -
- -
2,961,051
2026
- -
- -
- -
- -
3,104,064

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20.15
- -
- -
- -
154.13
2025
- -
- -
- -
- -
147.54
2026
- -
- -
- -
- -
229.64

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
63.85
2025
- -
- -
- -
- -
67.6
2026
- -
- -
- -
- -
66.15
Similar Companies
TGC Ventures International, Inc. (TGVN)
Yamashita Health Care Holdings,Inc. (9265.T)
Healthlead Public Company Limited (HL.BK)
Sigma Healthcare Limited (SIG.AX)
Galenica AG (GALE.SW)
Public Joint-Stock Company PROTEK (PRTK.ME)
Business
Alfresa Holdings Corporation, established in 2003 and headquartered in Tokyo, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import, and export of pharmaceuticals, diagnostic reagents, medical devices, and related equipment; it operates dispensing pharmacies and supports Japan's healthcare supply chain as the nation's leading ethical pharmaceuticals wholesaler. The company operates through key segments including Ethical Pharmaceuticals Wholesaling, which delivers prescription drugs, diagnostic reagents, medical devices, equipment, and materials to hospitals, clinics, and pharmacies via a nationwide network of distribution centers; Self-Medication Products Wholesaling, offering over-the-counter drugs, health foods, and supplements to drugstores as a total healthcare merchandising wholesaler; Manufacturing, producing active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices at facilities compliant with GMP and QMS standards, including contract manufacturing; Dispensing Pharmacy and Related Businesses, providing community-based family pharmacy services with home healthcare support; Regenerative Medicine–Related Business, encompassing cell material supply, specified cell-processed products, and CMO/CDMO services; Overseas Business through joint ventures in China and Vietnam for pharmaceuticals, medical devices, and reagents; and other operations such as SPD services, CRO, and PMS. Alfresa Holdings maintains extensive geographic operations across Japan with over 200 distribution bases, 177 dispensing pharmacies, and production sites including plants in Okayama, Gunma, Akita, and Osaka; internationally, it focuses on Asia via entities like REMEJE PHARMACEUTICALS (CHINA) CO., LTD. and Alfresa Codupha Healthcare Vietnam Co., Ltd. Recent developments include a March 2025 business alliance and memorandum of understanding with Minaris Regenerative Medicine and Cell Resources Corporation to enhance cell therapy development, manufacturing, and distribution capabilities; a January 2025 capital and business alliance with GEXVal Inc., securing JPY 300 million to accelerate clinical development of GXV-001 and improve pharmaceutical access; a January 2025 share acquisition and alliance with Medley Inc. via Alfresa Corporation to advance digital transformation and electronic medication records for pharmacies; a November 2025 basic business alliance with KeyPharma Inc. for exclusive transportation and distribution rights of KP8011, a subacute spinal cord injury treatment; a strategic partnership with HekaBio to expand biopharma and medtech portfolios in CNS and regenerative medicine; and a December 2025 pact with CMIC Holdings to build a vaccination support platform. In April 2025, the company launched its 25-27 Mid-term Management Plan, Vision 2032 Stage 2, emphasizing total supply chain services expansion, growth investments in regenerative medicine and health tech, core business strengthening, and sustainability to target net sales of JPY 3,330 billion by fiscal 2027 and JPY 4 trillion by 2032.